Stephen Kanes
CIK 1612859 · Chief Medical Officer · last filed 2026-06-24
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
SAGE price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
3RD FLOOR 1 ASHLEY ROAD, ALTRINCHAM
CHESHIRE, X0 WA14 2DT
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Centessa Pharmaceuticals plc (CNTA) Delisted | Chief Medical Officer | 0 | $40.50 | $0 | $0 | 3 | 2026-06-24 |
| Sage Therapeutics, Inc. (SAGE) Delisted | Chief Medical Officer | 13,471 | $8.68 | $116.9K | -$14.44M | 25 | 2021-10-21 |
Recent Filings · Page 3 of 3
28 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-09-29 | Sage Therapeutics, Inc. (SAGE) Delisted | Mixed | +15,000 | -$269.1K | EDGAR |
| 2015-09-01 | Sage Therapeutics, Inc. (SAGE) Delisted | Sell (S) | −12,000 | -$637.4K | EDGAR |
| 2015-07-29 | Sage Therapeutics, Inc. (SAGE) Delisted | Mixed | −3,000 | -$345.9K | EDGAR |
| 2015-06-25 | Sage Therapeutics, Inc. (SAGE) Delisted | Mixed | — | -$441.7K | EDGAR |
| 2015-03-27 | Sage Therapeutics, Inc. (SAGE) Delisted | Sell (S) | −5,400 | -$278.0K | EDGAR |
| 2015-02-27 | Sage Therapeutics, Inc. (SAGE) Delisted | Sell (S) | −6,000 | -$252.3K | EDGAR |
| 2015-01-27 | Sage Therapeutics, Inc. (SAGE) Delisted | Mixed | −6,000 | -$223.7K | EDGAR |
| 2014-07-23 | Sage Therapeutics, Inc. (SAGE) Delisted | Buy (P) | +3,000 | $54.0K | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).